Cerity Partners LLC Increases Stock Holdings in Zoetis Inc. $ZTS

Cerity Partners LLC boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 32.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 325,061 shares of the company’s stock after purchasing an additional 78,738 shares during the quarter. Cerity Partners LLC owned approximately 0.07% of Zoetis worth $50,693,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Scott & Selber Inc. lifted its holdings in shares of Zoetis by 0.6% during the 2nd quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock worth $1,817,000 after acquiring an additional 67 shares during the period. North Star Asset Management Inc. grew its holdings in Zoetis by 4.9% in the second quarter. North Star Asset Management Inc. now owns 1,441 shares of the company’s stock valued at $225,000 after purchasing an additional 67 shares during the period. Secure Asset Management LLC increased its position in Zoetis by 2.9% during the second quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock worth $382,000 after purchasing an additional 68 shares during the last quarter. Moment Partners LLC raised its stake in Zoetis by 3.2% during the second quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock worth $367,000 after purchasing an additional 72 shares during the period. Finally, CVA Family Office LLC boosted its holdings in shares of Zoetis by 6.7% in the 2nd quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock valued at $183,000 after purchasing an additional 74 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Performance

Shares of ZTS stock opened at $118.69 on Monday. The firm has a market capitalization of $52.31 billion, a price-to-earnings ratio of 19.98, a price-to-earnings-growth ratio of 2.46 and a beta of 0.97. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $181.85. The business has a 50 day simple moving average of $133.77 and a 200 day simple moving average of $147.57.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The business had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. During the same period in the previous year, the business earned $1.58 earnings per share. The company’s revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st were paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date of this dividend was Friday, October 31st. Zoetis’s payout ratio is currently 33.67%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. UBS Group cut their price objective on Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a report on Wednesday, November 5th. Piper Sandler upped their target price on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Stifel Nicolaus reduced their price target on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research report on Tuesday, November 18th. Argus restated a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Finally, Morgan Stanley decreased their target price on Zoetis from $211.00 to $175.00 and set an “overweight” rating for the company in a research note on Monday, November 10th. Six equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, Zoetis currently has a consensus rating of “Moderate Buy” and an average target price of $178.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.